Table 2. Inhibition of CYP11B2 and CYP11B1 by Compounds 25−32.

| IC50 value (nM)a,b |
IC50 value (nM)a,b |
|||||||
|---|---|---|---|---|---|---|---|---|
| n | no. | CYP11B1 | CYP11B2 | sfc | no. | CYP11B1 | CYP11B2 | sfc |
| 25 | 5 | 30 | 5.9 | 26 | 75 | 677 | 9.0 | |
| 0 | 27 | 3 | 11 | 3.4 | 30 | >1000 | >1000 | |
| 1 | 28 | 4 | 8 | 2.0 | 31 | >1000 | >1000 | |
| 2 | 29 | 80 | 290 | 3.6 | 32 | >1000 | >1000 | |
| MTPd | 15 | 72 | 4.8 | |||||
| ETOd | 0.5 | 0.1 | 0.2 | |||||
| KTZd | 127 | 67 | 0.5 | |||||
Mean value of at least three experiments. The deviations were within <±25%.
Hamster fibroblasts expressing human CYP11B1 or CYP11B2; substrate 11-deoxycorticosterone, 100 nM.
sf: IC50 (CYP11B2)/IC50 (CYP11B1).
MTP, metyrapone; ETO, etomidate; and KTZ, ketoconazole.